Evaluating and Improving the Cardiovascular Drug Supply for Better Global Health
The World Health Organization and its member states have agreed to the ambitious goal of reducing the risk of premature mortality from noncommunicable diseases, including heart disease and stroke, by 25% by 2025. This voluntary goal includes a national health system response target of "80% availability of the affordable basic technologies and essential medicines, including generics, required to treat major noncommunicable diseases in both public and private facilities." 1 A 2012 United Nations report 2 estimated that essential medicines were available in 52% and 68% of public and private pharmacies, respectively, between 2007 and 2011, which demonstrates this availability gap. While this health system response target assumes that the available medicines will contain the active pharmaceutical ingredient at the stated level, data from some studies, such as those focused on malaria, 3 suggest that these drugs fail chemical analysis in up to one-third of samples and thus may not achieve disease prevention and control. In this issue of JAMA Cardiology, Antignac et al 4 take an important initial step toward evaluating the medicine quality of common drugs used for cardiovascular disease prevention and control in 10 sub-Saharan African countries using standardized methods from 2012 to 2014. The authors use highquality reversed-phase liquid chromatography with tandem mass spectrometry, which is a sophisticated, relatively expensive, and reliable method. Cheaper, field-based, real-time methods to evaluate drug quality, such as the Global Pharma Health Fund Minilab or other similar platforms, will likely be even more useful for larger-scale efforts in the future. The authors use strict thresholds to define poor drug quality that some may debate, but their overall findings emphasize the scope and importance of drug safety not only in sub-Saharan Africa but all around the world, particularly in an era of globalized drug manufacturing and distribution in the absence of any global law or treaty against medicine crime. Drugs on national and global essential medicines lists, including the medicines evaluated by Antignac et al, represent priority medicines for surveillance.
To improve drug quality, the World Health Organization has created a Global Surveillance and Monitoring System for substandard, spurious, falsely labeled, falsified, and counterfeit medical products, which was launched in western Africa in 2013 following the development of the African Medicines Regulatory Harmonization Initiative in 2009. The World Health Organization provides technical support, including training, to member states for addressing suspected medical products while facilitating international collaboration among national focal points. This network seeks national-level reporting on regulatory capacity, international collaboration, and identification of major needs and challenges and will report its findings to the World Health Assembly in 2017. Improving and maintaining the safety of the global medicine supply is a shared priority for many stakeholders, including patients, physicians, governments, and payers as well as legitimate pharmaceutical manufacturers, who all benefit from a safe and effective medicine supply chain. To my knowledge, most reports have focused on drugs for communicable diseases to date. Data from Antignac et al highlight the growing importance of access to safe, essential medicines for preventing and controlling the leading causes of global deaths, namely heart disease and stroke, to achieve the "25×25" goal. Methods | The source cohort is a Johns Hopkins Hospital institutional review board-approved prospective open cohort of consecutive patients with MMD referred to the Electrophysiology Service. The cohort was divided into 2 sections. Those with magnetic resonance imaging and/or additional genetic testing provided written informed consent. However, those who did not undergo testing beyond our clinical routine were enrolled in a deidentified consent-exempt registry. We retrospectively summarized data on 136 patients with MMD-I and 28 patients with MMD-II with genetically confirmed diagnosis and baseline ECG between January 1997 and August 2014. Of all patients, 124 (76%) were unrelated, 12 patients (7%) belonged to 4 separate families (3 individuals per family), and 28 patients (17%) belonged to 14 separate families (2 individuals per family). After exclusion of ECGs with only paced or non-version-prepared late gadolinium enhancement images were obtained at baseline evaluation using a 1.5-T scanner in 71 patients. An investigator, masked to demographic and ECG data, retrieved imaging measurements performed by 3 attending Letters physicians at our institution. Conduction abnormalities were defined as PR of at least 240 milliseconds and QRS of at least 120 milliseconds. Left ventricular dysfunction was defined as ejection fraction less than 55% on echocardiography. Generalized estimating equations were used to examine the association of longitudinally repeated ECG measurements with baseline characteristics, while adjusting for data clustering per patient and families (all patients) and the association of repeated ECG measurements with LV dysfunction in the subgroup with repeated ECG data (27 patients).
Results | At baseline, patients with MMD-I had significantly longer PR and QRS intervals compared with patients with MMD-II ( Table 1) . In MMD-I, the incidences of PR at least 240 milliseconds and QRS at least 120 milliseconds during a mean (SD) follow-up duration of 5.54 (4.98) years (calculated from the first to the last clinical visit) were 19.2% and 11.7%, respectively. In contrast, patients with MMD-II experienced no incident PR abnormalities, despite similar incidence of QRS abnormalities. Nonspecific intraventricular conduction delays made up the most common QRS morphology when duration of at least 120 milliseconds was observed. In the longitudinal generalized estimating equations model, older age at diagnosis (+7.7 milliseconds per 10 years; 95% CI, 0.7-14.7; P = .03) and family history of sudden death (+22 milliseconds; 95% CI, 4.3-39.9; P = .02) were associated with prolongation, whereas MMD-II (−48.7 milliseconds per 10% higher; 95% CI, −78.6 to 18.9; P = .001) and higher baseline ejection fraction (−9.7 milliseconds; 95% CI −14.8 to 4.7 ; P < .001) were associated with stability or reduction of QRS interval during follow-up. Hypertension was more prevalent in patients with MMD-II (6 of 28 [21.4%] vs 6 of 136 [4.4%]; P = .02), but prevalence of dyslipidemia, diabetes, and coronary disease did not differ between the 2 groups. There was a trend toward higher prevalence of LV dysfunction at baseline with MMD-II (16 of 136 [11.8%] vs 5 of 28 [17.9%]; P = .41). However, no incident LV dysfunction was noted among patients with MMD-II in contrast to 2% among patients with MMD-I. Late gadolinium enhancementwas observed in 10 patients (14.1%) (3 anteroseptal, 3 posterior, 2 inferior, 1 lateral, and 1 diffuse) on cardiac magnetic resonance, with no significant difference between the 2 groups. In multivariable analysis, LV dysfunction was independently associated with atrial fibrillation (OR, 2.7; 95% CI, 1.8 -32.3; P < .001) and age at diagnosis (OR, 1.7 per year; 95% CI, 1.07-2.75; P = .03). In a longitudinal model (Table 2) , an incident 10-millisecond increase in QRS duration was associated with 3.5% decrease in ejection fraction in the subsequent year (−3.45; 95% CI, −4.87 to −2.03; P < .001).
Discussion | This study was limited by a retrospective design with potential for selection bias, differential clinical follow-up among subgroups, and interobserver bias of imaging studies. Nevertheless, this large, single-center cohort enables us to conclude that the prevalence of critically prognostic conduction abnormalities and LV dysfunction is very high in MMD, at greater than 20% and greater than 10%, respectively. Incident QRS prolongation exceeding 10 milliseconds is associated with decreased LV function the subsequent year. Based on these findings, yearly ECG examinations and symptom/ QRS prolongation-prompted LV function evaluation should be considered. Here, a threshold of 5 ng/L is not used to diagnose myocardial infarction but to risk stratify patients in whom the diagnosis is uncertain.
3 Negative predictive value is the appropriate and accepted method of evaluating tests of exclusion, analogous to D-dimer testing, and is determined in those without a diagnosis of myocardial infarction at presentation. Sensitivity is determined only in those patients with a diagnosis of myocardial infarction and does not include the target population in whom the risk stratification threshold is being applied. As such, defining the optimal threshold for risk stratification based on diagnostic sensitivity is inappropriate and misleading. Carlton et al 2 state that we did not openly report diagnostic sensitivity. We report the NPV, as this is the most appropriate measure. However, in the interest of transparency, a cardiac troponin concentration less than 5 ng/L at presentation had a sensitivity of 98.6% (95% CI, 97.7-99.4) for myocardial infarction or cardiac death at 30 days. Furthermore, this threshold is specific for the high-sensitivity cardiac troponin I assay; evaluating performance in cohorts in which the diagnosis was determined using an array of less precise cardiac troponin I and T assays is potentially misleading. How many of the events missed by the risk stratification threshold of 5 ng/L had high-sensitivity cardiac troponin I concentrations above the 99th percentile on serial testing? Negative predictive value is influenced by disease prevalence, and it is therefore important to determine whether this approach is consistent across different populations. While this ought to be the major strength of their study, Carlton et al 2 did
not report the prevalence of the primary outcome in patients without myocardial infarction at presentation or the NPV of cardiac troponin concentrations less than 5 ng/L for each cohort separately. In our cohort, the primary outcome occurred in 3.8% of patients without myocardial infarction at presentation. 1 We have modeled how variation in prevalence affects the NPV. Reassuringly, if a threshold of 5 ng/L is applied to a population with double the prevalence (8%), the NPV remains 99% or greater. Given the highest reported prevalence of myocardial infarction is 7%, 4 we believe our findings are generalizable and could be widely applied across different health care settings.
